Exelixis Q2 2025 slides: cabozantinib franchise grows 19% YoY, NET launch gains traction
PositiveFinancial Markets

Exelixis has reported a strong performance in Q2 2025, with its cabozantinib franchise experiencing a remarkable 19% year-over-year growth. This growth is significant as it reflects the increasing acceptance and utilization of cabozantinib in the market. Additionally, the launch of NET is gaining traction, indicating that Exelixis is successfully expanding its product offerings. This positive trend not only boosts the company's revenue but also enhances its position in the competitive pharmaceutical landscape, making it a noteworthy development for investors and stakeholders.
— Curated by the World Pulse Now AI Editorial System












